Cardiac Imaging

Which Imaging Is Best for an Asymptomatic Patient with Intermediate Coronary Artery Disease Risk?

·
Which Imaging Is Best for an Asymptomatic Patient with Intermediate Coronary Artery Disease Risk?

A 55-year-old man with well-controlled hypertension and a family history of premature coronary artery disease (CAD) is in your office for an annual physical. He feels well, exercises regularly, and has no chest pain, shortness of breath, or other cardiac symptoms. You calculate his 10-year atherosclerotic cardiovascular disease (ASCVD) risk, and it falls into the intermediate-risk category. This scenario presents a common clinical crossroads: the patient’s risk is not low enough to ignore, but not high enough to warrant aggressive therapy without further data. Is imaging indicated to refine his risk and guide management, specifically regarding statin therapy? This article provides a step-by-step workflow for this exact situation, explaining why the American College of Radiology (ACR) finds CT coronary calcium to be Usually Appropriate for initial imaging.

Who Fits This Clinical Scenario?

This guidance applies to a specific patient profile: an asymptomatic adult who, after a comprehensive risk assessment, is determined to be at intermediate risk for future coronary artery disease events. Correctly identifying this patient is crucial for appropriate test selection.

Inclusion Criteria:

  • Asymptomatic: The patient must have no signs or symptoms suggestive of coronary ischemia, such as anginal chest pain, dyspnea on exertion, or anginal equivalents. This workflow is for primary prevention and risk stratification, not for evaluating symptoms.
  • Intermediate Risk: This is typically defined by a 10-year ASCVD risk score between 7.5% and 20% using the Pooled Cohort Equations. This category represents the population where clinical uncertainty about initiating or intensifying preventive therapies (like statins) is highest.

Exclusion Criteria (Patients who fit a different workflow):

  • Low-Risk Patients: Individuals with a 10-year ASCVD risk below 7.5% generally do not require imaging for risk stratification, as the likelihood of finding significant disease is low and may not change management.
  • High-Risk Patients: Those with a 10-year ASCVD risk above 20%, or with conditions like diabetes or established CAD, are already candidates for intensive medical therapy. Imaging is typically not needed for the initial decision to start a statin, as it is already strongly indicated.
  • Symptomatic Patients: Any patient with symptoms concerning for angina falls under different ACR guidelines for suspected stable ischemic heart disease or acute chest pain, which prioritize functional testing or coronary CTA to assess for flow-limiting stenosis.

What Diagnoses Are You Working Up in This Scenario?

In an asymptomatic, intermediate-risk individual, the goal of imaging is not to diagnose a specific acute condition but to stratify the patient’s future risk by directly visualizing the underlying disease process. The “differential” is less about distinct diseases and more about quantifying the extent of subclinical atherosclerosis to guide preventive care.

Subclinical Coronary Atherosclerosis
This is the primary target of the investigation. The presence and quantity of calcified plaque in the coronary arteries is a direct measure of the cumulative burden of atherosclerosis. Identifying subclinical disease confirms that the patient’s risk factors have manifested as pathology, providing a powerful rationale to initiate or intensify preventive therapies like statins and to more aggressively manage blood pressure and other modifiable risks. The imaging result can reclassify a patient from “intermediate risk” to a higher or lower category, resolving clinical uncertainty.

Absence of Coronary Atherosclerosis
A key potential finding is the complete absence of calcified plaque (a calcium score of zero). This is a powerful negative risk marker, associated with a very low risk of cardiovascular events over the subsequent 5-10 years. Such a finding can provide reassurance and support a shared decision-making conversation about deferring statin therapy, especially if the patient is hesitant or at risk for side effects, a concept sometimes referred to as “de-risking.”

Non-Coronary Incidental Findings
While not the primary goal, any CT scan of the chest carries the potential to identify incidental findings. These can include lung nodules, hiatal hernias, or thoracic aortic ectasia. While important to recognize and manage, these are secondary to the main clinical question of coronary risk stratification.

Why Is CT Coronary Calcium the Recommended Study for This Presentation?

The ACR Appropriateness Criteria rate CT coronary calcium as Usually Appropriate for this scenario because it directly and non-invasively answers the central clinical question: what is this patient’s true atherosclerotic burden? The result, known as the Agatston score, is a robust and well-validated predictor of future cardiac events that significantly improves risk stratification beyond traditional risk factors alone.

The rationale for this recommendation is threefold:

  1. Direct Visualization of Disease: Unlike functional tests or serum biomarkers, a coronary artery calcium (CAC) score provides a direct, quantitative measure of calcified plaque. This shifts the clinical focus from statistical risk (based on population data) to the actual pathology present in the individual patient.
  2. Actionable Results: A CAC score has clear implications for management. A score of zero may justify deferring statin therapy, while a high score (e.g., >100) provides a compelling reason to initiate and adhere to treatment. This ability to reclassify risk is the test’s main value in the intermediate-risk population.
  3. Favorable Safety Profile: The study is fast, requires no IV contrast, and involves a relatively low radiation dose (☢☢☢ 1-10 mSv). This makes it a suitable screening and risk-stratification tool.

In contrast, other imaging modalities are rated lower for this specific purpose:

  • CTA coronary arteries with IV contrast is rated May be appropriate. While it provides more anatomical detail, including visualization of non-calcified plaque and luminal stenosis, it is a more complex test. It requires IV contrast, often heart rate control with beta-blockers, and typically involves a higher radiation dose. For a purely asymptomatic patient, the primary question is about plaque burden, not luminal stenosis, making the additional information and complexity of a CTA unnecessary for initial risk stratification.
  • US echocardiography transthoracic stress is rated Usually not appropriate. Stress testing is designed to detect flow-limiting stenosis that causes ischemia under stress. In an asymptomatic patient, the pre-test probability of significant ischemia is low. This test does not quantify atherosclerotic burden and is more likely to yield false-positive results, potentially leading to unnecessary downstream invasive procedures. It answers a different clinical question than the one being asked in this scenario.

Once you’ve decided on CT coronary calcium, our protocol guide covers the technique, contrast, and reading principles: CT Coronary Calcium Score.

What’s Next After CT Coronary Calcium? Downstream Workflow

The result of the CT coronary calcium score directly informs the next steps in management, facilitating a shared decision-making process with the patient.

  • If the CAC Score is 0 (Zero): This finding confers a very low 10-year risk of a major adverse cardiac event. It is a powerful argument for “de-risking” the patient. In this case, it is reasonable to defer statin therapy and focus on reinforcing lifestyle modifications. The conversation can be revisited in 5-7 years, or sooner if risk factors change.
  • If the CAC Score is 1-99 (Mild): This confirms the presence of subclinical atherosclerosis. For patients in this range, particularly those over age 55, initiating statin therapy is favored. The presence of any plaque, even a small amount, indicates the atherosclerotic process has begun.
  • If the CAC Score is 100 or Greater (Moderate to Severe): A score of 100 or higher, or a score above the 75th percentile for the patient’s age and sex, indicates a significant plaque burden and a substantially increased risk. Statin therapy is strongly recommended. This result can be a powerful motivator for patient adherence to both medication and lifestyle changes.
  • If the CAC Score is Very High (e.g., >400 or >1000): While still asymptomatic, a very high score places the patient in a risk category equivalent to those with known CAD. Consider more aggressive risk factor modification, including lower LDL targets. Some clinicians may consider further evaluation with functional testing, though this is not universally recommended in the absence of symptoms.

Pitfalls to Avoid (and When to Get Help)

Navigating this workflow requires careful patient selection and interpretation. Here are common pitfalls to avoid:

  • Ordering in Low-Risk Patients: A CAC score is a low-yield test in a low-risk individual and may lead to incidental findings and patient anxiety without changing management.
  • Ordering in High-Risk Patients: In a high-risk patient (e.g., ASCVD >20% or a person with diabetes), statin therapy is already indicated. A CAC score is unnecessary to make this decision.
  • Misinterpreting a Zero Score: A CAC score of zero is highly reassuring but does not mean zero risk forever. It reflects the absence of calcified plaque; non-calcified plaque can still be present. Risk should be periodically reassessed.
  • Over-reacting to Incidental Findings: Non-cardiac findings are common. Have a clear plan for how to address them without causing undue alarm or triggering an unnecessary cascade of further testing.

If the patient develops any cardiac symptoms (e.g., chest pain, exertional dyspnea) before or after the scan, the entire clinical context changes. At that point, escalate the workup to evaluate for symptomatic, potentially obstructive disease, which may involve cardiology consultation and functional testing or coronary CTA.

Related ACR Topics and Tools

This article covers one specific scenario in depth. For a broader overview of imaging for asymptomatic patients at all risk levels, or to explore the technical details of the recommended study, the following resources are valuable.

Frequently Asked Questions

Does a coronary calcium score of zero mean the patient has no plaque?

Not necessarily. A calcium score of zero indicates the absence of calcified plaque, which is a very strong negative risk marker. However, it does not rule out the presence of non-calcified, or ‘soft,’ plaque. Despite this, the clinical data overwhelmingly show that individuals with a zero score have a very low risk of a major cardiac event in the subsequent 5-10 years.

Why not just order a coronary CTA to see everything, including soft plaque?

While a coronary CTA provides more comprehensive anatomical information, it is rated ‘May be appropriate’ rather than ‘Usually Appropriate’ for this scenario because it is a more intensive test. It requires IV contrast (with associated risks of allergy and nephropathy), often requires beta-blockers to control heart rate, and typically involves a higher radiation dose than a non-contrast calcium score. For the specific question of risk stratification in an asymptomatic intermediate-risk patient, the simpler, safer, and well-validated calcium score is sufficient to guide therapy.

How often should a coronary artery calcium score be repeated?

There is no firm consensus on repeat testing. For a patient with a baseline score of zero, repeating the scan in 5-7 years may be reasonable if their risk profile changes. For those with a non-zero score who are on medical therapy, the utility of a repeat scan to monitor progression is less clear and not routinely recommended, as management is unlikely to change based on the new score alone.

What if my patient’s ASCVD risk score is borderline, like 7.0%?

For patients on the border between low and intermediate risk (e.g., 5% to 7.5%), a CAC score can be a valuable tie-breaker. The presence of risk-enhancing factors (like strong family history, inflammatory diseases, or chronic kidney disease) would further support using a CAC score to clarify the need for statin therapy. A shared decision-making conversation is key in these borderline cases.

Is a CT coronary calcium scan covered by insurance?

Coverage for coronary calcium scoring for screening and risk stratification is variable and depends on the specific payer and plan. While it is increasingly covered for intermediate-risk patients to guide statin therapy decisions, some plans may still consider it a non-covered screening test. It is often available as a relatively low-cost self-pay procedure.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026